Clinical Trial Results:
Placebo-Controlled Study of Mometasone Furoate Nasal Spray (MFNS) 200 mcg QD in the Relief of Nasal Congestion Associated With Seasonal Allergic Rhinitis (SAR)
Summary
|
|
EudraCT number |
2014-004919-36 |
Trial protocol |
Outside EU/EEA |
Global end of trial date |
17 Nov 2008
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
05 Apr 2016
|
First version publication date |
19 Jul 2015
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
P05529
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT00732381 | ||
WHO universal trial number (UTN) |
- | ||
Other trial identifiers |
Merck Protocol Number: MK-0887-157 | ||
Sponsors
|
|||
Sponsor organisation name |
Merck Sharp & Dohme Corp.
|
||
Sponsor organisation address |
2000 Galloping Hill Road, Kenilworth, NJ, United States, 07033
|
||
Public contact |
Clinical Trials Disclosure, Merck, Sharp & Dohme Corp., ClinicalTrialsDisclosure@merck.com
|
||
Scientific contact |
Clinical Trials Disclosure, Merck, Sharp & Dohme Corp., ClinicalTrialsDisclosure@merck.com
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
Yes
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
17 Nov 2008
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
17 Nov 2008
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
17 Nov 2008
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
The primary objective of this study was to assess the efficacy in relieving the symptom of nasal congestion with MFNS 200 mcg given once daily compared to placebo in subjects with symptomatic SAR.
|
||
Protection of trial subjects |
This study was conducted in conformance with Good Clinical Practice standards and applicable country and/or local statutes and regulations regarding ethical committee review, informed consent, and the protection of human subjects participating in biomedical research.
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
29 Jul 2008
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
United States: 351
|
||
Worldwide total number of subjects |
351
|
||
EEA total number of subjects |
0
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
25
|
||
Adults (18-64 years) |
318
|
||
From 65 to 84 years |
8
|
||
85 years and over |
0
|
|
|||||||||||||||||||
Recruitment
|
|||||||||||||||||||
Recruitment details |
Participants 12 years of age or older with symptomatic SAR were recruited. Additional inclusion and exclusion criteria applied. | ||||||||||||||||||
Pre-assignment
|
|||||||||||||||||||
Screening details |
Participants were screened for study inclusion over Day -14 to Day -3. | ||||||||||||||||||
Period 1
|
|||||||||||||||||||
Period 1 title |
Overall Study (overall period)
|
||||||||||||||||||
Is this the baseline period? |
Yes | ||||||||||||||||||
Allocation method |
Randomised - controlled
|
||||||||||||||||||
Blinding used |
Double blind | ||||||||||||||||||
Roles blinded |
Subject, Investigator, Carer, Assessor | ||||||||||||||||||
Arms
|
|||||||||||||||||||
Are arms mutually exclusive |
Yes
|
||||||||||||||||||
Arm title
|
Mometasone furoate nasal spray | ||||||||||||||||||
Arm description |
Mometasone furoate nasal spray 200 mcg QD (once per day) | ||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||
Investigational medicinal product name |
mometasone furoate
|
||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||
Other name |
MK-0887, Nasonex Nasal Spray
|
||||||||||||||||||
Pharmaceutical forms |
Nasal spray
|
||||||||||||||||||
Routes of administration |
Intranasal use
|
||||||||||||||||||
Dosage and administration details |
MFNS 50 mcg/spray: two sprays in each nostril once daily (ie, 200 mcg QD) for 15 days
|
||||||||||||||||||
Arm title
|
Placebo Nasal Spray | ||||||||||||||||||
Arm description |
Matching placebo nasal spray | ||||||||||||||||||
Arm type |
Placebo | ||||||||||||||||||
Investigational medicinal product name |
placebo
|
||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||
Other name |
|||||||||||||||||||
Pharmaceutical forms |
Nasal spray
|
||||||||||||||||||
Routes of administration |
Intranasal use
|
||||||||||||||||||
Dosage and administration details |
Matching placebo nasal spray: 2 sprays in each nostril once daily for 15 days
|
||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Mometasone furoate nasal spray
|
||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Mometasone furoate nasal spray 200 mcg QD (once per day) | ||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Placebo Nasal Spray
|
||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Matching placebo nasal spray | ||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Mometasone furoate nasal spray
|
||
Reporting group description |
Mometasone furoate nasal spray 200 mcg QD (once per day) | ||
Reporting group title |
Placebo Nasal Spray
|
||
Reporting group description |
Matching placebo nasal spray |
|
|||||||||||||
End point title |
The change from Baseline in average AM/PM PRIOR nasal congestion score over 15 days | ||||||||||||
End point description |
Nasal congestion was scored on a scale of 0 = none, 1 = mild, 2 = moderate, and 3 = severe symptoms. PRIOR (the subject's status over the previous 12 hours [reflective]). Baseline is the average score from the 3 days prior to the first dose of study drug.
|
||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
15 days of treatment
|
||||||||||||
|
|||||||||||||
Notes [1] - The standard deviation is pooled. [2] - The standard deviation is pooled. |
|||||||||||||
Statistical analysis title |
Comparison of Treatment Groups | ||||||||||||
Statistical analysis description |
The change from Baseline in average AM/PM PRIOR nasal congestion score over 15 days: MFNS 200 mcg daily vs placebo. The difference in LS means (MFNS - Placebo) was calculated from an ANCOVA model with treatment, site and baseline AM/PM PRIOR Nasal Congestion Score as covariates.
|
||||||||||||
Comparison groups |
Placebo Nasal Spray v Mometasone furoate nasal spray
|
||||||||||||
Number of subjects included in analysis |
351
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority | ||||||||||||
P-value |
= 0.006 | ||||||||||||
Method |
ANCOVA | ||||||||||||
Parameter type |
Difference in LS Means | ||||||||||||
Point estimate |
-0.15
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
-0.26 | ||||||||||||
upper limit |
-0.04 |
|
|||||||||||||
End point title |
The change from Baseline in average AM/PM PRIOR total nasal symptom score (TNSS) over 15 days | ||||||||||||
End point description |
Total nasal symptom score is a composite of 4 symptoms, each is scored on a scale of 0 = none, 1 = mild, 2 = moderate, 3 = severe. The total can range from 0 to 12. PRIOR (the subject's status over the previous 12 hours [reflective]). Baseline is the average score from the 3 days prior to the first dose of study drug.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
15 days of treatment
|
||||||||||||
|
|||||||||||||
Notes [3] - The standard deviation is pooled. [4] - The standard deviation is pooled. |
|||||||||||||
Statistical analysis title |
Comparison of Treatment Groups | ||||||||||||
Statistical analysis description |
The change from Baseline in average AM/PM PRIOR TNSS over 15 days: MFNS 200 mcg daily vs placebo. The difference in LS means (MFNS - Placebo) was calculated from an ANCOVA model with treatment, site and baseline AM/PM TNSS as covariates.
|
||||||||||||
Comparison groups |
Mometasone furoate nasal spray v Placebo Nasal Spray
|
||||||||||||
Number of subjects included in analysis |
351
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority | ||||||||||||
P-value |
< 0.001 | ||||||||||||
Method |
ANCOVA | ||||||||||||
Parameter type |
Difference in LS Means | ||||||||||||
Point estimate |
-0.83
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
-1.25 | ||||||||||||
upper limit |
-0.4 |
|
||||||||||||||||
Adverse events information [1]
|
||||||||||||||||
Timeframe for reporting adverse events |
Day 1 up to 30 days after study completion/discontinuation (up to 45 days)
|
|||||||||||||||
Assessment type |
Systematic | |||||||||||||||
Dictionary used for adverse event reporting
|
||||||||||||||||
Dictionary name |
MedDRA | |||||||||||||||
Dictionary version |
11.1
|
|||||||||||||||
Reporting groups
|
||||||||||||||||
Reporting group title |
Mometasone furoate nasal spray
|
|||||||||||||||
Reporting group description |
Mometasone furoate nasal spray 200 mcg QD (once per day) | |||||||||||||||
Reporting group title |
Placebo Nasal Spray
|
|||||||||||||||
Reporting group description |
Matching placebo nasal spray | |||||||||||||||
|
||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 5% | ||||||||||||||||
|
||||||||||||||||
Notes [1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported. Justification: No non-serious adverse events (incidence ≥ 5%) were reported during the study. |
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? No | |||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported |